Literature DB >> 16862181

RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene.

T Eguchi1, T Takaki, H Itadani, H Kotani.   

Abstract

As alterations in retinoblastoma (RB)/E2F pathway are commonly found in human cancers, the molecular mechanism underlying cell cycle deregulation caused by the mutations in the RB/E2F pathway needs to be investigated extensively. Compared with good understanding of RB/E2F functions in G1-S cell cycle progression, it is not fully understood how an abrogated RB pathway affects the G2-M phase of the cell cycle. Here, we report that disruption of RB accelerated G2-M progression in the presence of DNA damage by elevating the expression of a set of mitotic regulatory genes. We generated RB(+)- and (-)-matched cells using short hairpin RNA. In the RB(-) cells, the G2/M checkpoint mediated by a DNA-damaging agent was over-ridden. With microarray analysis, we found that the expression of key G2-M regulatory genes was upregulated in RB(-) cells. In particular, we demonstrated that the proto-oncogene ECT2 was directly regulated by E2Fs. Furthermore, suppression of ECT2 expression by small interfering RNA in RB(-) cells resulted in cytokinesis arrest, suggesting that RB(-) cells lack the regulation of E2F-mediated cytokinesis. These results indicate that aberrant ECT2 expression, observed in various human tumors, could be the direct result of RB/E2F pathway deficiency, thereby contributing to cell division in cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862181     DOI: 10.1038/sj.onc.1209810

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

Review 1.  Understanding cytokinesis failure.

Authors:  Guillaume Normand; Randall W King
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 2.  RB: mitotic implications of a tumour suppressor.

Authors:  Amity L Manning; Nicholas J Dyson
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

Review 3.  Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.

Authors:  Shinji Mizuarai; Hidehito Kotani
Journal:  Hum Genet       Date:  2010-10-26       Impact factor: 4.132

Review 4.  E2F4 function in G2: maintaining G2-arrest to prevent mitotic entry with damaged DNA.

Authors:  Dragos Plesca; Meredith E Crosby; Damodar Gupta; Alexandru Almasan
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

5.  CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase.

Authors:  Laetitia Seguin; Caroline Liot; Rym Mzali; Ryoko Harada; Aurelie Siret; Alain Nepveu; Jacques Bertoglio
Journal:  Mol Cell Biol       Date:  2008-11-17       Impact factor: 4.272

Review 6.  DNA microarray-based gene expression profiling of estrogenic chemicals.

Authors:  Ryoiti Kiyama; Yun Zhu
Journal:  Cell Mol Life Sci       Date:  2014-01-08       Impact factor: 9.261

Review 7.  The human intra-S checkpoint response to UVC-induced DNA damage.

Authors:  William K Kaufmann
Journal:  Carcinogenesis       Date:  2009-09-30       Impact factor: 4.944

8.  Molecular characterization of apoptosis induced by CARF silencing in human cancer cells.

Authors:  C T Cheung; R Singh; A R Yoon; M K Hasan; T Yaguchi; S C Kaul; C O Yun; R Wadhwa
Journal:  Cell Death Differ       Date:  2010-11-05       Impact factor: 15.828

Review 9.  pRB, a tumor suppressor with a stabilizing presence.

Authors:  Amity L Manning; Nicholas J Dyson
Journal:  Trends Cell Biol       Date:  2011-06-12       Impact factor: 20.808

Review 10.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.